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percentage of naive T cells than peripheral blood stem cells,
the presence or strength of the graft-versus-leukemia (GVL)
effect has been controversial. Using Japanese registry data,
we analyzed the impact of acute and chronic graft-versus-
host disease (GVHD) on outcomes after single UCBT.
Methods: We analyzed patients with acute leukemia or
myelodysplastic syndrome who underwent the ﬁrst UCBT (n
¼ 3,224) between 2000 and 2012 in Japan. The effect of acute
GVHD (aGVHD) on overall mortality, relapse, and non-
relapse mortality (NRM) was analyzed after adjusting for
other signiﬁcant variables among the engrafted patients,
whereas the effect of chronic GVHD (cGVHD) was analyzed
among the engrafted patients who survived without relapse
for at least 100 days. The occurrence of GVHD was treated as
a time-dependent covariate.
Results: The occurrence of grade 3 or 4 (G3-4) aGVHD was
signiﬁcantly associated with a higher risk of NRM (hazard
ratio [HR] 3.08, P < 0.001) than the occurrence of G0-1
aGVHD, in both the standard- and high-risk groups. The
occurrence of G2 or G3-4 aGVHD, as compared with G0-1
aGVHD, was signiﬁcantly associated with a low relapse rate
(G2 aGVHD: HR 0.80, P ¼ 0.003; G3-4 aGVHD: HR 0.71, P ¼
0.005). These resulted in the signiﬁcant association between
G2 aGVHD and low mortality (HR 0.79, P < 0.001), and G3-4
aGVHD and high mortality (HR 1.70, P < 0.001), as compared
with G0-1 aGVHD. The association between G3-4 aGVHD and
high mortality was stronger in the standard-risk group (HR
2.46, P < 0.001) than in the high-risk group (HR 1.40, P <
0.001). The occurrence of extensive cGVHD was associated
with a low relapse rate as comparedwith no cGVHD (HR 0.77,
P ¼ 0.046). The effect of limited cGVHD was signiﬁcant only
in the high-risk group (standard-risk: HR 1.07, P ¼ 0.673;
high-risk: HR 0.65, P ¼ 0.007). The occurrence of extensive
chronic GVHD was signiﬁcantly associated with high NRM
only in the standard-risk group (standard-risk, HR 1.46, P ¼
0.037; high-risk: HR 0.93, P ¼ 0.701). These resulted in the
signiﬁcant association between limited cGVHD and low
mortality in both groups, whereas extensive cGVHD was
associated with low mortality only in the high-risk group.
Conclusions: Similar to transplantations from a matched
sibling or an unrelated donor, G3-4 aGVHD should be pre-
vented because of its associated high overall and non-relapse
mortality rates, although acute GVHD was associated with
low relapse rates. Extensive cGVHD should be prevented
particularly in the standard-risk group because of its asso-
ciated high NRM. In the high-risk group, cGVHD was asso-
ciated with low relapse rates. The signiﬁcant association
between aGVHD or cGVHD and a low relapse rate supports
the presence of GVL effect in the UCBT even in the high-risk
group.Figure. Failure free survival in patients with late acute GVHD489
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Background: Late acute (LA) graft vs. host disease (GVHD) is
persistent, recurrent or new onset acute GVHD symptoms
more than 100 days after hematopoietic cell transplantation
(HCT). The aim of this analysis is to describe the onset,
course, and the morbidity and mortality associated with LA
GVHD.
Methods: A prospective cohort of patients was enrolled as
part of an observational study of immunemediated disorders
after HCTwithin the Chronic GVHD Consortium at 13 centers.
Patients with previous diagnosis of LA or chronic GVHD prior
to enrollment were excluded.
Results: Out of 913 patients in the study, 85 developed LA
GVHDwith a cumulative incidence of 11% at 2-year after HCT
(2-persistent, 40-recurrent and 43 de-novo). Median agewas
53.2 years, 70% received URD transplants, and graft source
was peripheral blood in 87%. 44% received myeloablative
conditioning, and 7% received ATG/Alemtuzumab. Median
time of onset for LA GVHD was 160 days (IQR 128-204) days
after HCT. Median follow-up for survivors after LA GVHD
diagnosis was 10.2 (range 0.7-25.9) months. 60% of patients
had biopsy proven LA GVHD. Single organ involvement at
diagnosis was seen in 59 patients (skin 39%, liver 14% and gut
47%), while 26 patients (31%) had2 organ involvement. 21%
of patients with liver GVHD had only transaminitis without
elevated bilirubin and hence were not included for acute
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Initial treatment included beginning or increasing systemic
steroids (69%), continuing calcineurin inhibitors (64%) or
beginning topical treatment (52%). Additional treatment was
added within the ﬁrst 28 days for 31% patients. Median lines
of treatment for the total duration of follow-upwere 1 (range
0-4).
Of the evaluable patients, 63/85 and 56/66 had a clinical
response (CR/PR) at 28 days and at 180 days respectively. 36%
developed recurrence of LA GVHD after a documented CR.
26% developed chronic GVHD after LA GVHD at a median of
169 (range 25-383) days after diagnosis of LA GVHD. Median
number of hospital days in the ﬁrst 6 months after the
diagnosis of LA GVHD was 15 (range 1-120) days. 25% had
discontinued immunosuppressive therapy (IST) at the time
of last follow-up with the median duration of IST being 12.8
(range 6.1-24.7) months after HCT. 9% relapsed and 22% died
with themain causes of death being GVHD, infection ormulti
organ failure. Median failure free survival (FFS) as deﬁned by
absence of relapse, death, addition of new IST or develop-
ment of chronic GVHD was 3.6 months (95% CI: 1.7-6.8)
(Figure). Median overall survival (OS) was 25.3 months. No
patient/transplant or GVHD related factors emerged as sig-
niﬁcant predictors for FFS or OS in univariate analysis.
Conclusions: The overall incidence of LA GVHD is low, but it
is associated with prolonged immunosuppression, poor
failure free and overall survival.490
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Introduction: Reduced intensity conditioning (RIC) regi-
mens decrease early toxicity after allogeneic hematopoietic
cell transplant (HCT), but their ultimate success depends
on establishing a graft-versus-tumor effect (GVT). Because
graft-versus-host disease (GVHD) and GVT are tightly linked,Figure 1complete elimination of GVHD may lead to an unintended
increased relapse risk in a RIC setting. Therefore, we tested a
novel GVHD prophylaxis regimen intended to preserve GVT
but minimize GVHD mortality.
Methods: 48 patients undergoing RIC unrelated donor
transplant (URD HCT) enrolled from 2009-2012 on a phase
II trial that added etanercept and extracorporeal photo-
pheresis (ECP) to a standard GVHD prophylaxis of tacroli-
mus and mycophenolate mofetil (MMF). The preferred RIC
was ﬂudarabine 160 mg/m2 + busulfan 6.4-12.8 mg/kg +/-
TBI 200 cGy. GVHD prophylaxis consisted of overlapping
agents as follows: Tacrolimus from d-3 to d56 (then
tapered over 4 months in the absence of acute GVHD),
MMF d0-28, etanercept 25 mg subcutaneously 2x weekly
from d0-56 (16 doses), and ECP beginning on d28. ECP was
given once weekly from d28-70, then every other week
until d100, then monthly until d180 for a total of 12
treatments. Donors were required to match to recipients
for 7-8/8 HLA loci.
Results: The median age of the study patients was 60 yr (18-
71). Donors were 7/8 (n¼14, 29%) or 8/8 (n¼34, 71%)
matched. Patients engrafted at a median of 12d (8-26d). The
12mo post-HCT end points for the entire study cohort were
as follows: overall survival 73% (95% CI 61-87) (Figure 1A),
non-relapse mortality (NRM) 21% (9-32), and relapse of 19%
(8-30). The cumulative incidence of grade II-IV acute GVHD
at d100 and 6mo was 46% (32-60) and 57% (42-71) respec-
tively, and for grade III-IV acute GVHD was 17% (6-27) and
19% (8-30). In an exploratory analysis (Figure 1B), GVHD that
developed after 8 doses of etanercept and at least one ECP
treatment (d28) was signiﬁcantly less lethal than GVHD that
developed before ECP began (6mo NRM 11% vs 40%, 12 mo
21% vs 50%; p¼0.04), which suggests that ECP prophylaxis
may ameliorate GVHD lethality. The possible beneﬁt of pro-
phylactic ECP on GVHD outcomes does not appear to be
related to delayed GVHD onset as NRM did not differ in
control patients diagnosed before or after d28. In 69
contemporaneous control patients with grade 2-4 GVHD,
6mo and 12 mo NRM was 32% and 39% respectively, and
there was no difference between patients that developed
GVHD after or before d28 (6mo 27% vs 36%,12mo 33% vs 44%;
p¼0.57).
Conclusions: Six month (83%) and 1yr survival (73%) was
excellent in older, frequently mismatched URD HCT pa-
tients, even though GVHD incidence was not lowered. An
exploratory analysis suggested that if prophylactic ECP has
beneﬁt, the effect is conﬁned to patients who start ECP
before GVHD develops. Strategies focusing on earlier de-
livery of ECP to URD HCT patients could be explored in
future studies..
